title: Re: Christan Walter, Bilal Al-Nawas, Knut A. Grötz, et al. Prevalence and risk factors of bisphosphonate-associated osteonecrosis of the jaw in prostate cancer patients with advanced disease treated with zoledronate. Eur Urol 2008;54:1066-72.
authors.forename: Alfredo
authors.initials: A
authors.lastname: Berruti
authors.forename: Cinzia
authors.initials: C
authors.lastname: Ortega
authors.forename: Vittorio
authors.initials: V
authors.lastname: Fusco
mesh_terms: D050071:Bone Density Conservation Agents / Q000009:adverse effects*; D004164:Diphosphonates / Q000009:adverse effects*; D006801:Humans; D007093:Imidazoles / Q000009:adverse effects*; D007571:Jaw Diseases / Q000139:chemically induced* / Q000453:epidemiology; D008297:Male; D010020:Osteonecrosis / Q000139:chemically induced* / Q000453:epidemiology; D015995:Prevalence; D011471:Prostatic Neoplasms / Q000188:drug therapy*; D012307:Risk Factors; D000077211:Zoledronic Acid
chemical_list: D050071:Bone Density Conservation Agents; D004164:Diphosphonates; D007093:Imidazoles; D000077211:Zoledronic Acid